Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings. The new data from the 1,178-patient FIBRONEER-ILD study showed ...
Reduction in force (RIF) job losses have started in earnest at US federal agencies, including the FDA and CDC, according to multiple media outlets which report that emails started to reach affected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback